Understanding the Performance of Merck’s Hospital Acute Care Drugs Noxafil and Cubicin
In 4Q17, Merck’s (MRK) Cubicin reported revenues of $92 million, which was ~23% lower on a YoY (year-over-year) basis but 1% higher on a QoQ (quarter-over-quarter) basis. In 4Q17, in the US and in international markets, Cubicin generated revenues of $40 million and $52 million, respectively, compared with $82 million and $36 million in 4Q16, which reflected a ~51% decline and 43% rise, respectively, YoY. In fiscal 2017, Cubicin reported revenues of $382 million, compared with $1.1 billion in 2016.